Toxic shock syndrome

Toxic shock syndrome is an acute, toxin-driven condition resulting from infection with toxin-producing bacteria, most commonly Staphylococcus aureus or Streptococcus pyogenes. The syndrome represents a hyperimmune response mediated by superantigens that cause non-specific binding between major histocompatibility complex class II molecules and T-cell receptors, triggering massive cytokine release. While streptococcal toxic shock syndrome is sometimes termed toxic-shock-like syndrome (TSLS), both forms share the fundamental pathophysiology of superantigen-mediated disease.

TSS presents with a characteristic tetrad of fever, rash resembling sunburn, desquamation (particularly on palms and soles), and hypotension that can progress to shock. Additional manifestations include malaise, confusion, and potential rapid progression to stupor, coma, or multiple organ failure. The underlying infection may produce focal signs depending on the site, such as mastitis, osteomyelitis, necrotizing fasciitis, or pneumonia. Staphylococcal TSS typically affects otherwise healthy individuals, while streptococcal cases often involve invasive infection with deeper tissue involvement.

Source-backed detail on geographic distribution and population-level burden is not yet available. TSS occurs in association with both community and healthcare settings, with cases linked to menstrual tampon use (staphylococcal) and various invasive infections (streptococcal). The disease's incidence is relatively low but carries substantial morbidity and mortality, particularly the streptococcal form. Surveillance systems typically track TSS as a notifiable condition given its severity and potential for outbreak identification.

TSS is not transmitted person-to-person; rather, it results from endogenous bacterial toxin production at sites of infection or colonization. Staphylococcal TSS classically associates with tampon use, particularly highly absorbent varieties, while streptococcal TSS arises from invasive infections entering deep tissues or the bloodstream. The disease mechanism involves superantigen production at the infection site, which then disseminates systemically to trigger the characteristic hyperinflammatory response.

Risk factors for staphylococcal TSS include use of very absorbent tampons and the presence of skin lesions, particularly in young children presenting with fever, hypotension, rash, vomiting, and/or diarrhea. Streptococcal TSS risk is associated with invasive infections, surgical wounds, and conditions facilitating bacterial tissue invasion. The disease can affect previously healthy individuals, making universal vigilance important in clinical settings. Outcomes are poorer when source control is delayed, underscoring the importance of rapid recognition across all patient populations.

Prevention strategies center on minimizing infection risk and early intervention. For menstrual-associated TSS, recommendations include avoiding high-absorbency tampons, changing tampons frequently, and considering alternative menstrual products. Prompt treatment of skin lesions, wounds, and invasive infections reduces risk of toxin-mediated complications. Healthcare providers should maintain awareness of TSS in patients with compatible presentations, particularly those with risk factors or focal infections known to predispose to toxin production.

TSS surveillance requires clinical alertness to the characteristic syndrome, as diagnosis is primarily symptom-based using established criteria. Monitoring should capture both confirmed and probable cases, with attention to the underlying etiologic agent given differing management implications and outcomes. Surveillance data help identify potential outbreaks, track epidemiologic trends, and assess the burden of severe invasive streptococcal and staphylococcal disease. Case reporting facilitates public health response and quality improvement in recognition and management.

1. 1 Wikidata. toxic shock syndrome.
2. 2 Wikipedia. Toxic shock syndrome - Wikipedia.

ICD-10

ICD-11

Total cases

0

Peak month

—

Coverage

0 reporting countries · —